Centrexion Therapeutics Corp.

Centrexion Therapeutics Corp., a biotechnology company, develops and commercializes non-opioid, and nonaddictive chronic pain drugs. It focuses on developing therapies for chronic pain conditions such as osteoarthritis, neuropathic pain, and chronic lower back pain. The company’s products include CNTX-4975, which is in Phase III clinical trials to treat moderate to severe pain due to knee osteoarthritis (OA), as well as in Phase II clinical trials to treat Morton’s neuroma and canine OA; and CNTX-0290, a product candidate in Phase I clinical trials for chronic pain associated with inflammatory, neuropathic, and mixed pain conditions. It is also developing CNTX-6970, which is in Phase I clinical trials to treat inflammatory pain; CNTX-2022, a high-concentration topical gel formulation of lidocaine that is in Phase I clinical trials to treat superficial musculoskeletal pain, dermatologic itch and pain, and superficial neuropathic pain; and CNTX-6016, a pre-clinical stage product candidate to treat chronic neuropathic pain. Centrexion Therapeutics Corp. was formerly known as Centrexion Corporation. Centrexion Therapeutics Corp. was incorporated in 2013 and is based in Boston, Massachusetts.